Simon Cancer Center

Indiana University

Indianapolis, IN

Not currently accepting

CARTITUDE-2

Phase 2, Open-Label Study Evaluating the Use of an Investigational CAR-T Cell therapy in Participants with Multiple Myeloma
Learn more
  • CAR T Cell
  • BCMA
  • Phase 2

Accepting patients

DREAMM5

Platform Study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination with Anti-Cancer Treatments in Participants with Relapsed/Refractory Multiple Myeloma (RRMM)
Learn more
  • Antibody Drug Conjugate (ADC)
  • Gamma-Secretase Inhibitor
  • BCMA
  • Phase 2
  • Has results

Not yet accepting

MagnetisMM-30

A Phase 1B, Open-Label Study of Elranatamab in Combination with Iberdomide in Participants with Relapsed Refractory Multiple Myeloma
Learn more
  • Bispecific Antibody
  • BCMA
  • CD3
  • Phase 1

Accepting patients

Triplet Induction + 1 or 2-Drug Maintenance

A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of "Intermediate Fit" Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent Maintenance
Learn more
  • Monoclonal Antibody
  • CD38
  • Maintenance
  • Randomization
  • Phase 3

Accepting patients

DRAMMATIC

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC)
Learn more
  • Monoclonal Antibody
  • CD38
  • Maintenance
  • Phase 3

Accepting patients

Linvoseltamab

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Learn more
  • Bispecific Antibody
  • BCMA
  • Phase 1

Accepting patients

EQUATE

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Learn more
  • Monoclonal Antibody
  • CD38
  • Phase 3
2 hidden based on your filters. Show All